ReviewInternational journal of molecular sciences2022
Immunothrombosis and the Role of Platelets in Venous Thromboembolic Diseases.
Review in International journal of molecular sciences, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 42 citations in OpenAlex.
- Article
- Platelet FcɣRIIa: a novel biomarker of risk for thromboembolism and death in cancer.Journal of thrombosis and thrombolysis · 2026Observational
- Protease-activated Receptor 1 Targeted Screening of Potential Antithrombotic Compounds with Hemostatic Activity from Polygonum Amplexicaule D. Don var. Sinense Forb.Cardiovascular drugs and therapy · 2026Article
- Diagnostic Performance of Immature Platelet Fraction in Patients with Suspected Deep Vein Thrombosis.Healthcare (Basel, Switzerland) · 2026Article
- G protein-coupled receptor-mediated platelet thrombus formation.Current opinion in hematology · 2026Review
- Exploratory Diagnostic Performance of On-Admission Soluble CD40 Ligand for Distinguishing Acute Pulmonary Embolism from Hospitalization-Requiring Community-Acquired Pneumonia: A Single-Center Observational Study.Diagnostics (Basel, Switzerland) · 2026Article
- Development, internal testing, and external validation of an interpretable machine-learning model for predicting imaging-confirmed in-hospital postoperative deep vein thrombosis in older patients with patellar fractures.BMC medical informatics and decision making · 2026Article
- Prognostic value of the early D-dimer/fibrinogen ratio in critically ill patients requiring vascular surgery: a retrospective study.BMC anesthesiology · 2026Article
- Machine learning integration of bulk and single-cell RNA-Seq data reveals COPS2 as a central immune regulator in deep vein thrombosis.American journal of translational research · 2026Article
- Risk factors and a predictive nomogram for in-hospital deep vein thrombosis in elderly patients with multiple chronic conditions.American journal of translational research · 2026Article
- circRNA-associated-ceRNA networks in patients with traumatic tracheal stenosis.Scientific reports · 2025Article
- ECMO-induced coagulopathy: strategic initiatives for research and clinical practice (a workshop report of the NHLBI).Blood vessels, thrombosis & hemostasis · 2025Review
- A mendelian randomization study on the association between 731 types of immune cells and 91 types of blood cells with venous thromboembolism.Thrombosis journal · 2025Article
- Investigating the dual causative pathways linking immune cells and venous thromboembolism via Mendelian randomization analysis.Thrombosis journal · 2025Article
- Role of PCSK9 inhibitors in venous thromboembolism: current evidence and unmet clinical needs.European heart journal. Cardiovascular pharmacotherapy · 2025Review
- From Cell Interactions to Bedside Practice: Complete Blood Count-Derived Biomarkers with Diagnostic and Prognostic Potential in Venous Thromboembolism.Journal of clinical medicine · 2025Review
- Thromboinflammation vs. immunothrombosis: strategies for overcoming anticoagulant resistance in COVID-19 and other hyperinflammatory diseases. Is ROTEM helpful or not?Frontiers in immunology · 2025Review
- Elevated C-reactive protein and D-dimer to predict venous thromboembolism in patients with bladder cancer.Frontiers in immunology · 2025Article
- Baseline platelet count and long-term clinical outcomes in patients with acute venous thromboembolism: a prospective cohort study.Annals of hematology · 2024Article
- Overview of Venous Thromboembolism and Emerging Therapeutic Technologies Based on Nanocarriers-Mediated Drug Delivery Systems.Molecules (Basel, Switzerland) · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Venous thromboembolism (VTE) is the third leading cardiovascular cause of death and is conventionally treated with anticoagulants that directly antagonize coagulation. However, recent data have demonstrated that also platelets play a crucial role in VTE pathophysiology. In the current review, we outline how platelets are involved during all stages of experimental venous thrombosis. Platelets mediate initiation of the disease by attaching to the vessel wall upon which they mediate leukocyte recruitment. This process is referred to as immunothrombosis, and within this novel concept inflammatory cells such as leukocytes and platelets directly drive the progression of VTE. In addition to their involvement in immunothrombosis, activated platelets can directly drive venous thrombosis by supporting coagulation and secreting procoagulant factors. Furthermore, fibrinolysis and vessel resolution are (partly) mediated by platelets. Finally, we summarize how conventional antiplatelet therapy can prevent experimental venous thrombosis and impacts (recurrent) VTE in humans.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.